Source comparison
Receptor Pathway Mechanisms — GHRH vs Ghrelin Signaling
CJC-1295 no DAC binds to GHRH receptors (GHRH-R) on somatotroph cells in the anterior pituitary, triggering cAMP-mediated signaling cascades that increase the amplitude of growth hormone release during naturally occurring pulses. The peptide doesn't create new
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC binds to GHRH receptors (GHRH-R) on somatotroph cells in the anterior pituitary, triggering cAMP-mediated signaling cascades that increase the amplitude of growth hormone release during naturally occurring pulses. The peptide doesn't create new pulses. It enhances the magnitude of pulses already governed by your hypothalamic rhythm, which in humans follows an ultradian pattern with major secretory episodes occurring roughly every 3–5 hours and peaking during deep sleep. The 'no DAC' designation means this version lacks the Drug Affinity Complex modification found in CJC-1295 DAC (which extends half-life to 6–8 days but introduces non-pulsatile GH elevation that some research suggests may reduce IGF-1 conversion efficiency).
- Ipamorelin operates through an entirely separate pathway. It's a pentapeptide ghrelin mimetic that binds selectively to the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor ghrelin uses to signal hunger and initiate GH secretion. What makes Ipamorelin clinically significant is receptor selectivity. Unlike GHRP-2 or hexarelin, Ipamorelin doesn't activate cortisol release via ACTH stimulation or prolactin secretion, both of which can produce unwanted metabolic side effects during chronic use. A study published in the Journal of Endocrinology (Raun et al., 1998) demonstrated that Ipamorelin produces dose-dependent GH release with an ED50 of approximately 80 nmol/kg in rats, comparable to GHRP-6 but without measurable cortisol or prolactin elevation even at supraphysiological doses.
- The pharmacological reality: when you administer CJC-1295 no DAC alone, you're optimizing the pulses your body already generates. If your hypothalamus isn't firing a release signal at that moment, CJC sits idle. When you administer Ipamorelin alone, you're creating a new pulse event through ghrelin pathway activation regardless of where you are in your natural cycle. When you stack them, you're doing both. Amplifying endogenous pulses while simultaneously triggering additional release through a second independent receptor system. This is why CJC1295 Ipamorelin 5MG 5MG formulations exist as pre-mixed research compounds. The synergy isn't theoretical, it's documented in plasma GH concentration curves.